A number of naturally occurring hepatitis B virus (HBV) mutants unable to synthesize the hepatitis B e antigen (HBeAg) have been identified in patients characterized by HBV DNA and anti-HBe in their serum. Because the analysis of the HBV-associated DNA and antigens in the liver tissue is still not c
Enzymatic amplification and sequence analysis of precore/core DNA in HBsAg-positive patients
✍ Scribed by Dr. Karin Ljunggren; Alistair H. Kidd
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 675 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Serum or plasma from 69 HBsAg‐positive patients was tested for the presence of precore/core gene specific DNA by the polymerase chain reaction (PCR). In both healthy individuals (n = 26) and chronic carriers (n = 25), there was a strong correlation between presence of circulating anti‐HBe and the absence of detectable HBV genome in serum. In 18 serum samples where HBsAg was the only detectable marker, i.e., anti‐HBc‐negative specimens, HBV DNA could be detected in three samples. HBV strains from 21 of the 24 PCR‐positive samples were sequenced over the precore/core junction. A stop codon at the end of the precore region, described by other workers, was found in strains from two blood donors, one of whom had detectable HBeAg in serum. Conversely, HBV strains from the three anti‐HBc‐negative patients where DNA of the HBV precore region could be amplified and who had no detectable serum HBeAg or anti‐HBe did not have this stop codon. The study indicates that further investigations are required before lack of HBeAg can be correlated with evidence of mutations in the precore region.
📜 SIMILAR VOLUMES
## Abstract Hepatitis B virus (HBV) infections are occasionally associated with unusual serological profiles which may be attributed to the lack of immune responsiveness of the patients or to variants of the virus. The term HBV~2~ was introduced to describe potential variants of HBV which do not el
A highly sensitive polymerase chain reaction (PCR) was used to analyse serum samples from HBsAg-positive patients in Sweden. Forty-two chronic carriers were tested, five of whom were of Swedish origin. Of the total, there were 13 HBeAg-positive and 27 anti-HBe-positive patients, while 1 patient was
This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
## Abstract This retrospective study investigated the prevalence of hepatitis B virus (HBV) in 192 stored sera from human immunodeficiency virus (HIV) positive South African patients initiating antiretroviral therapy (ART), and explored the implications of HBV–HIV co‐infection on laboratory diagnos